Taxol, Taxoids, and Related Taxanes

Natural Products in Medicinal Chemistry

Volumn , Issue , 2014, Pages 127-180

  Ojima, Iwao ^a   Kamath, Anushree ^a   Seitz, Joshua D ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Anticancer; Antitubercular agents; Cancer; Taxanes; Taxoid; Taxol

Indexed keywords

EID: 84926483780     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527676545.ch04     Document Type: Chapter

References (318)

1. Wall, M.E., Wani, M.C., Cook, C.E., Palmer, C.E., and McPhail, A.T. (1966) Plant antitumor agents: I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. Journal of the American Chemical Society, 88, 3888-3894.
2. Wani, M.C., Taylor, H.L., Wall, M.E., Coggan, P., and McPhail, A.T. (1971) Plant antitumor agents: VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. Journal of the American Chemical Society, 93, 2325-2327.
3. Wani, M.C., Kepler, J.A., Thompson, J.B., Wall, M.E., and Levine, S.G. (1970) Plant antitumour agents: alkaloids -synthesis of a pentacyclic camptothecin precursor. Journal of the Chemical Society. Chemical Communications, 404.
4. Wall, M.E., Wani, M.C., and Taylor, H.L. (1976) Isolation and chemical characterization of antitumor agents from plants. Cancer Treatment Reports, 60, 1011-1014.
5. Patel, R.N. (1998) Tour de paclitaxel: biocatalysis for semisynthesis. Annual Review of Microbiology, 98, 361-395.
6. Fuchs, D.A. and Johnson, R.K. (1978) Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treatment Reports, 62, 1219-1222.
7. Horwitz, S.B., Fant, J., and Schiff, P.B. (1979) Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665-667.
8. Horwitz, S.B. (2004) Personal recollections on the early development of taxol. Journal of Natural Products, 67, 136-138.
9. Blume, E. (1991) Government moves to increase taxol supply. Journal of the National Cancer Institute, 83, 1054-1056.
10. Cragg, G.M., Schepartz, S.A., Suffness, M., and Grever, M.R. (1993) The taxol supply crisis: new NCI policies for handling the large-scale production of novel natural product anticancer and anti-HIV agents. Journal of Natural Products, 56, 1657-1668.
11. Chauviére, G., Guénard, D., Picot, F., Sénilh, V., and Potier, P. (1981) Structural analysis and biochemical study of isolated products of the yew: Taxus baccata L. (Taxaceae). Comptes Rendus de l'Académie des Sciences. Série II, 293, 501-503.
12. Suffness, M. (1995) Taxol: Science and Applications;, CRC Press, New York.
13. Rowinsky, E.K., Onetto, N., Canetta, R.M., and Arbuck, S.G. (1992) Taxol: the first of the taxanes, an important new class of anti-cancer agents. Seminars in Oncology, 19, 646-662.
14. Rowinsky, E.K. (1997) The development and clinical utility of the taxane class of anti-microtubule chemotherapy agents. Annual Review of Medicine, 48, 353-374.
15. Wang, Y.-F., Shi, Q.-W., Dong, M., Kiyota, H., Gu, Y.-C., and Cong, B. (2011) Natural taxanes: developments since 1828. Chemical Reviews, 11, 7652-7709.
16. Baloglu, E. and Kingston, D.G.I. (1999) The taxane diterpenoids. Journal of Natural Products, 62, 1448-1472.
17. Jennewein, S. and Croteau, R. (2001) Taxol: biosynthesis, molecular genetics and biotechnological applications. Applied Microbiology and Biotechnology, 57, 13-19.
18. Vazquez, A. and Williams, R.M. (2000) Studies on the biosynthesis of taxol: synthesis of taxa-4(20),11(12)-diene-2a, 5a-diol. The Journal of Organic Chemistry, 65, 7865-7869.
19. Gueritte-Voegelein, F., Guenard, D., and Potier, P. (1987) Taxol and derivatives: a biogenetic hypothesis. Journal of Natural Products, 50, 9-18.
20. Potier, P. (1992) Search and discovery of new antitumour compounds. Chemical Society Reviews, 21, 113-119.
21. 1: Science and Applications (ed. M. Suffness), CRC Press, Boca Raton, FL, pp. 191-208.
22. Zhang, Z. and Jia, Z. (1990) Taxanes from Taxus yunnanensis. Phytochemistry, 29, 3673-3675.
23. Miller, R.W., Powell, R.G., Smith, C.R., Jr., Arnold, E., and Clardy, J. (1981) Antileukemic alkaloids from Taxus wallichiana Zucc. The Journal of Organic Chemistry, 46, 1469-1474.
24. Bala, S., Uniyal, G.C., Chattopadhyay, S.K., Tripathi, V., Sashidhara, K.V., Kulshrestha, M., Sharma, R.P., Jain, S.P., Kukreja, A.K., and Kumar, S. (1999) Analysis of taxol and major taxoids in Himalayan yew, Taxus wallichiana. Journal of Chromatography. A, 858, 239-244.
25. Senilh, V., Guéritte, F., Guénard, D., Colin, M., and Potier, P. (1984) Hemisynthesis of new taxol analogs: investigation of their interaction with tubulin. Comptes Rendus de l'Académie des Sciences, Série II, 299, 1039-1043.
26. Denis, J.-N., Greene, A.E., Guenard, D., Gueritte-Voegelein, F., Mangatal, L., and Potier, P. (1988) A highly efficient, practical approach to natural taxol. Journal of the American Chemical Society, 110, 5917-5919.
27. 1: Science and Applications (ed. M. Suffness), CRC Press, New York, pp. 97-121.
28. Ojima, I., Habus, I., Zhao, M., Georg, G.I., and Jayasinghe, R. (1991) Efficient and practical asymmetric synthesis of the taxol C-13 side chain, N-benzoyl-(2R, 3S)-3-phenylisoserine, and its analogs via chiral 3-hydroxy-4-aryl-b-lactams through chiral ester enolate-imine cyclocondensation. The Journal of Organic Chemistry, 56, 1681-1683.
29. Ojima, I., Habus, I., Zhao, M., Zucco, M., Park, Y.H., Sun, C.-M., and Brigaud, T. (1992) New and efficient approaches to the semisynthesis of taxol and its C-13 side chain analogs by means of b-lactam synthon method. Tetrahedron, 48, 6985-7012.
30. Kingston, D.G., Chaudhary, A.G., Gunatilaka, A.A.L., and Middleton, M.L. (1994) Synthesis of taxol from baccatin III via an oxazoline intermediate. Tetrahedron Letters, 35, 4486-4489.
31. Didier, E., Fouque, E., and Commerçon, A. (1994) Expeditious semisynthesis of docetaxel using 2-trichloromethyl-1,3-oxazolidine as side-chain protection. Tetrahedron Letters, 35, 3063-3064.
32. Didier, E., Fouque, E., Taillepied, I., and Commerçon, A. (1994) 2-Monosubstituted-1,3-oxazolidines as improved protective groups of N-Boc-phenylisoserine in docetaxel preparation. Tetrahedron Letters, 35, 2349-2352.
33. Baloglu, E. and Kingston, D.G.I. (1999) A new semisynthesis of paclitaxel from baccatin III. Journal of Natural Products, 62, 1068-1071.
34. Holton, R.A., Somoza, C., Kim, H.-B., Liang, F., Biediger, R.J., Boatman, P.D., Shindo, M., Smith, S.C., Kim, S., Nadizadeh, H., Suzuki, Y., Tao, C., Vu, P., Tang, S., Zhang, P., Murthi, K.K., Gentile, L.N., and Liu, J.H. (1994) First total synthesis of taxol: 1. Functionalization of the B ring. Journal of the American Chemical Society, 116, 1597-1598.
35. Holton, R.A., Somoza, C., Kim, H-Baik, Liang, F., Biediger, R.J., Boatman, P.D., Shindo, M., Smith, S.C., Kim, S., Nadizadeh, H., Suzuki, Y., Tao, C., Vu, P., Tang, S., Zhang, P., Murthi, K.K., Gentile, L.N., Liu, J.H. (1994) First total synthesis of taxol: 2. Completion of the C and D rings. Journal of the American Chemical Society, 116, 1599-1600.
36. Danishefsky, S.J., Masters, J.J., Young, W.B., Link, J.T., Snyder, L.B., Magee, T.V., Jung, J.K., Isaacs, R.C.A., Bornmann, W.G., Alaimo, C.A., Coburn, C.A., and Dii Grandi, M.J. (1996) Total synthesis of baccatin III and taxol. Journal of the American Chemical Society, 118, 2843-2859.
37. Nicolaou, K.C., Yang, Z., Liu, J.J., Ueno, H., Nantermet, P.G., Guy, R.K., Claiborne, C.F., Renaud, J., Couladouros, E.A., Paulvannan, K., and Sorensen, E.J. (1994) Total synthesis of taxol. Nature, 367, 630-634.
38. Morihira, K., Hara, R., Kawahara, H., Nishimori, T., Nakamura, N., Kusama, H., and Kuwajima, I. (1998) Enantioselective total synthesis of (-)taxol. Journal of the American Chemical Society, 120, 12980-12981.
39. Wender, P.A., Badham, N.F., Conway, S.P., Floreancig, P.E., Glass, T.E., Houze, J.B., Krauss, N.E., Lee, D., Marquess, D.G., McGrane, P.L., Meng, W., Natchus, M.G., Shuker, A.J., Sutton, J.C., and Taylor, R.E. (1997) The pinene path to taxanes: 6. A concise stereocontrolled synthesis of taxol. Journal of the American Chemical Society, 119, 2757-2758.
40. Mukaiyama, T., Shiina, I., Iwadare, H., Saitoh, M., Nishimura, T., Ohkawa, N., Sakoh, H., Nishimura, T., Tani, Y.-I., Hasegawa, M., Yamada, K., and Saitoh, K. (1999) Asymmetric total synthesis of taxol. Chemistry -A European Journal, 5, 121-161.
41. Nicolaou, K.C., Nantermet, P.G., Ueno, H., Guy, R.K., and Sorensen, E.J. (1995) Total synthesis of taxol: 1. Retrosynthesis, degradation and reconstitution. Journal of the American Chemical Society, 117, 624-633.
42. Nicolaou, K.C., Liu, J.-J., Yang, Z., Ueno, H., Guy, R.K., Sorensen, E.J., Claiborne, C.F., Guy, R.K., Hwang, C.-K., Nakada, M., and Nantermet, P.G. (1995) Total synthesis of taxol: 2. Construction of the A and C ring intermediates and initial attempts to construct the ABC ring system. Journal of the American Chemical Society, 117, 634-644.
43. Nicolaou, K.C., Yang, Z., Liu, J.-J., Nantermet, P.G., Claiborne, C.F., Guy, R.K., and Shibayama., K. (1995) Total synthesis of taxol: 3. Formation of taxol's ABC ring skeleton. Journal of the American Chemical Society, 117, 645-652.
44. Nicolaou, K.C., Ueno, H., Liu, J.-J., Nantermet, P.G., Yang, Z., Renaud, J., Paulvannan, K., and Chadha, R. (1995) Total synthesis of taxol: 4. The final stages and completion of the synthesis. Journal of the American Chemical Society, 117, 653-659.
45. Wender, P.A., Badham, N.F., Conway, S.P., Floreancig, P.E., Glass, T.E., Gränicher, C., Houze, J.B., Jänichen, J., Lee, D., Marquess, D.G., McGrane, P.L., Meng, W., Mucciaro, T.P., Mühlebach, M., Natchus, M.G., Paulsen, H., Rawlins, D.B., Satkofsky, J., Shuker, A.J., Sutton, J.C., Taylor, R.E., and Tomooka, K. (1997) The pinene path to taxanes: 5. Stereocontrolled synthesis of a versatile taxane precursor. Journal of the American Chemical Society, 119, 2755-2756.
46. Kusama, H., Hara, R., Kawahara, S., Nishimori, T., Kashima, H., Nakamura, N., Morihira, K., and Kuwajima, I. (2000) Enantioselective total synthesis of taxol. Journal of the American Chemical Society, 122, 3811-3820.
47. Wheeler, N.C., Jech, K., Masters, S., Brobst, S.W., Alvarado, A.B., Hoover, A.J., and Snader, K.M. (1992) Effects of genetic, epigenetic and environmental factors on taxol content in Taxus brevifolia and related species. Journal of Natural Products, 55, 432-440.
48. McCormick, D. (1993) Right of reply. Bio/ Technology, 11, 26.
49. Agency, U.E.P. (2004) Greener Synthetic Pathways Award: Bristol-Myers Squibb Company: Development of a Green Synthesis for TAXOL Manufacture via Plant Cell Fermentation and Extraction, www.epa.gov/greenchemistry/pubs/pgcc/winners/gspa04.html.
50. Bai, J., Kitabatake, M., Toyoizumi, M., Fu, L., Zhang, S., Dai, S., Sakai, J., Hirose, K., Yamori, T., Tomida, A., Tsuruo, T., and Ando, M. (2004) Production of biologically active taxoids by a callus culture of Taxus cuspidata. Journal of Natural Products, 67, 58-63.
51. Ma, W., Park, G.L., Gomez, G.A., Neider, M.H., Adams, T.L., Aynsley, J.S., Sahai, O.P., Smith, R.J., Stahlhut, R.W., and Hylands, P.J. (1994) New bioactive taxoids from cell cultures of Taxus baccata. Journal of Natural Products, 57, 116-122.
52. Fett-Neto, A.G., DiCosmo, F., Reynolds, W.F., and Sakata, K. (1992) Cell culture of Taxus as a source of the antineoplastic drug taxol and related taxanes. Bio/ Technology, 10, 1572-1575.
53. Edgington, S.M. (1991) Taxol: out of the woods. Bio/Technology, 9, 933-938.
54. Strobel, G., Yang, X., Sears, J., Kramer, R., Sidhu, R.S., and Hess, W.M. (1996) Taxol from Pestalotiopsis microspora, an endophytic fungus of Taxus wallachiana. Microbiology (Reading, England), 142, 435-440.
55. Stierle, A., Strobel, G., and Stierle, D. (1993) Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of pacific yew. Science, 260, 214-216.
56. Wang, J., Li, G., Lu, H., Zheng, Z., Huang, Y., and Su, W. (2000) Taxol from Tubercularia sp. strain TF5, an endophytic fungus of Taxus mairei. FEMS Microbiology Letters, 193, 249-253.
57. Li, J.Y., Strobel, G., Sidhu, R., Hess, W.M., and Ford, E.J. (1996) Endophytic taxol producing fungi from bald cypress Taxodium distichum. Microbiology (Reading, England), 142, 2223-2226.
58. Weiss, R., Donehower, R.C., and Wiernik, P.H. (1990) Hypersensitivity reactions from taxol. Journal of Clinical Oncology, 8, 1263-1268.
59. Rowinsky, E.K., Eisenhauer, E.A., and Chaudhry, V. (1993) Clinical toxicities encountered with taxol. Seminars in Oncology, 20 (Suppl. 3), 1-15.
60. Rowinsky, E.K., Gilbert, M., and McGuire, W.P. (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. Journal of Clinical Oncology, 9, 1692-1703.
61. McGuire, W.P., Hoskins, W.J., and Brady, M.F. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine, 334, 1-6.
62. Rowinsky, E.K. and Donehower, R.C. (1995) Paclitaxel (taxol). New England Journal of Medicine, 332, 1004-1014.
63. Nogales, E., Wolf, S., Khan, I., Luduena, R., and Downing, K. (1995) Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature, 375, 424-427.
64. Andreu, J.M., Bordas, J., Diaz, J.F., deAncos, J.G., Gil, R., Medrano, F.J., Nogales, E., Pantos, E., and Towns-Andrews, E. (1992) Low resolution structure of microtubules in solution: synchrotron X-ray scattering and electron microscopy of taxol-induced microtubules assembled from purified tubulin in comparison with glycerol and MAP-induced microtubules. Journal of Molecular Biology, 226, 169-184.
65. Diaz, J., Valpuesta, J., Chacon, P., Diakun, G., and Andreu, J. (1998) Changes in microtubule protofilament number induced by taxol binding to an easily accessible site. The Journal of Biological Chemistry, 272, 33803-33810.
66. Sackett, D. and Fojo, T. (1997) Taxanes. Cancer Chemotherapy and Biological Response Modifiers, 17, 59-79.
67. Schiff, P. and Horwitz, S. (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proceedings of the National Academy of Sciences of the United States of America, 77, 1561-1565.
68. Huizing, M.T., Keung, A.C., Rosing, H., van derKuij, V., tenBokkel Huinink, W.W., Mandjes, I.M., Dubbelman, A.C., Pinedo, H.M., and Beijen, J.H. (1993) Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. Journal of Clinical Oncology, 11, 2127-2135.
69. Jordan, M. and Wilson, L. (1998) Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Current Opinion in Cell Biology, 10, 123-130.
70. Long, B. and Fairchild, C. (1994) Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Research, 54, 4355-4361.
71. Donaldson, K., Goolsby, G., and Wahl, A. (1994) Cytotoxicity of the anti-cancer agents cisplatin and taxol during cell proliferation and the cell cycle. International Journal of Cancer, 57, 847-855.
72. Sorger, P., Dobles, M., Tournebize, R., and Hyman, A. (1997) Coupling cell division and cell death to microtubule dynamics. Current Opinion in Cell Biology, 9, 807-814.
73. Huisman, C., Ferreira, C., Broker, L., Rodriguez, J., Smit, E., Postmus, P., Kruyt, F., and Giaccone, G. (2002) Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clinical Cancer Research, 8, 596-606.
74. Oyaizu, H., Adachi, Y., Taketani, S., Tokunaga, R., Fukuhara, S., and Ikehara, S. (1999) A crucial role of caspase 3 and caspase 8 in paclitaxel-induced apoptosis. Molecular Cell Biology Research Communications, 2, 36-41.
75. Mielgo, A., Torres, V., Clair, K., Barbero, S., and Stupack, D. (2009) Paclitaxel promotes a caspase 8-mediated apoptosis through death effector domain association with microtubules. Oncogene, 28, 3551-3562.
76. Park, S.-J., Wu, C.-H., Gordon, J., Zhong, X., Emami, A., and Safa, A. (2004) Taxol induces caspase 10-dependent apoptosis. The Journal of Biological Chemistry, 279, 51057-51067.
77. Shtil, A., Madlekar, S., Yu, R., Walter, R., Hagen, K., Tan, T., Roninson, I., and Kong, A. (1999) Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells. Oncogene, 18, 377-384.
78. Subbaramaiah, K., Hart, J., Norton, L., and Dannenberg, A. (2000) Microtubule-interfering agents stimulate the transcription of cyclooxygenase: 2. Evidence for involvement of ERK1/2 and p38 mitogen-activated protein kinase pathways. The Journal of Biological Chemistry, 275, 14838-14845.
79. Blagosklonny, M. and Fojo, T. (1999) Molecular effects of paclitaxel: myths and reality (a critical review). International Journal of Cancer, 83, 151-156.
80. Haldar, S., Chintapalli, J., and Croce, C. (1996) Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells. Cancer Research, 56, 1253-1255.
81. Haldar, S., Basu, A., and Croce, C. (1997) Bcl2 is the guardian of microtubule integrity. Cancer Research, 57, 229-233.
82. Blagosklonny, M., Giannakakou, P., El-Deiry, W., Kingston, D., Higgs, P., Neckers, L., and Fojo, T. (1997) Raf1/bcl2 phosphorylation: a step from microtubule damage to cell death. Cancer Research, 57, 130-135.
83. Ibrado, A., Liu, L., and Bhalla, K. (1997) Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human AML HL-60 cells. Cancer Research, 57, 1109-1115.
84. Chun, E. and Lee, K.-Y. (2004) Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochemical and Biophysical Research Communications, 315, 771-779.
85. Gazitt, Y., Rothenberg, M., Hilsenback, S., Fey, V., Thomas, C., and Montegomrey, W. (1998) Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. International Journal of Oncology, 13, 839-848.
86. Srivastava, R., Mi, Q.-S., Hardwick, J., and Longo, D. (1999) Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 96, 3775-3780.
87. Callagy, G., Pharoah, P., and Pinder, S. (2006) Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clinical Cancer Research, 12, 2468-2475.
88. Yoshino, T., Shiina, H., and Urakami, S. (2006) Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clinical Cancer Research, 12, 6116-6125.
89. Mabuchi, S., Ohmichi, M., Kimura, A., Hisamoto, K., Hayakawa, J., Nishio, Y., Adachi, K., Takahashi, K., Arimoto-Ishida, E., Nakatsuji, Y., Tasaka, K., and Murata, Y. (2002) Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. The Journal of Biological Chemistry, 277, 33490-33500.
90. Pushkarev, V., Starenki, D., Saenko, V., Namba, H., Kurebayashi, J., Tronko, M., and Yamashita, S. (2004) Molecular mechanisms of the effects of low concentrations of taxol in anaplastic thyroid cancer cells. Endocrinology, 145, 3143-3152.
91. Maudrell, K., Antonsson, B., Magnenat, E., Camps, M., Muda, M., Chabert, C., Gillerron, C., Boschert, U., Vial-Knecht, E., Martinou, J.-C., and Arkinstall, S. (1997) Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of constitutively active GTP binding protein Rac1. The Journal of Biological Chemistry, 272, 25238-25242.
92. Shiah, S., Chuang, S., and Kuo, M. (2001) Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells. Molecular Pharmacology, 59, 254-262.
93. Blagosklonny, M., Schulte, T., Nguyen, P., Trepel, J., and Neckers, L. (1996) Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Research, 56, 1851-1854.
94. Huang, Y., Sheikh, M., Fornance, A., and Holbrook, N. (1999) Serine protease inhibitor TPCK prevents taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells. Oncogene, 18, 3431-3439.
95. Ahn, J.-H., Eum, K.-H., and Lee, M. (2009) The enhancement of Raf-1 kinase activity by knockdown of Spry2 is associated with high sensitivity to paclitaxel in v-Ha-ras-transformed NIH 3T3 fibroblasts. Molecular and Cellular Biochemistry, 332, 189-197.
96. Okano, J.-I. and Rustgi, A. (2001) Paclitaxel induces prolonged activation of the Ras/ MEK/ERK pathway independently of activating the programmed cell death machinery. The Journal of Biological Chemistry, 276, 19555-19564.
97. Ferlini, C., Cicchillitti, L., Raspaglio, G., Bartollino, S., Cimitan, S., Bertucci, C., Mozzetti, S., Gallo, D., Persico, M., Fattorusso, C., Campiani, G., and Scambia, G. (2009) Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Research, 69, 6906-6914.
98. Szakacs, G., Paterson, J., Ludwig, J., Booth-Genthe, C., and Gottesman, M. (2006) Targeting multidrug resistance in cancer. Nature Reviews. Drug Discovery, 5, 219-234.
99. Gottesman, M. and Pastan, I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annual Review of Biochemistry, 62, 385-427.
100. Yeh, J., Hsu, W., Wang, J., Ho, S., and Kao, A. (2003) Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration; International Review of Thoracic Diseases, 70, 32-35.
101. Penson, R., Oliva, E., Skates, S., Glyptis, T., Fuller, A.J., Goodman, A., and Selden, M. (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecologic Oncology, 93, 98-106.
102. Johnatty, S., Beesley, J., Paul, J., Fereday, S., Spurdle, A., Webb, P., Byth, K., Marsh, S., McLeod, H., Harnett, P., Brown, R., deFazio, A., and Chenevix-Trench, G. (2008) ABCB (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/ carboplatin chemotherapy. Clinical Cancer Research, 14, 5594-5601.
103. Leonard, G., Fojo, T., and Bates, S. (2003) The role of ABC transporters in clinical practice. Oncologist, 8, 411-424.
104. Orr, G., Verdier-Pinard, P., McDaid, H., and Horwitz, S. (2003) Mechanisms of taxol resistance related to microtubules. Oncogene, 22, 7280-7295.
105. Giannakakou, P., Gussio, R., Nogales, E., Downing, K., Zaharevitz, D., Bollbuck, B., Poy, G., Sackett, D., Nicolaou, K., and Fojo, T. (2000) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 97, 2904-2909.
106. Monzo, M., Rosell, R., Sanchez, J., Lee, J., O'Brate, A., Gonzalez-Larriba, J., Alberola, V., Lorenzo, J., Nunez, L., Ro, J., and Martin, C. (1999) Paclitaxel resistance in non-small-cell lung cancer associated with b-tubulin gene mutations. Journal of Clinical Oncology, 17, 1786-1793.
107. Jaffrezou, J., Dumontet, C., Derry, W., Duran, G., Chen, G., Tsuchiya, E., Wilson, L., Jordan, M., and Sikic, S. (1995) Novel mechanism of resistance of paclitaxel in human K562 leukemia cells by combined selection with PSC833. Oncology Research, 7, 517-527.
108. Kavallaris, M., Kuo, D.Y., Burkhart, C.A., Regl, D.L., Norris, M.D., Haber, M., and Horwitz, S.B. (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific b-tubulin isotypes. The Journal of Clinical Investigation, 100, 1282-1293.
109. Ranganathan, S., Benetatos, C., Colarusso, P., Dexter, D., and Hudes, G. (1998) Altered b-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. British Journal of Cancer, 77, 562-566.
110. Seve, P., Isaaac, S., Tredan, O., Souquet, P.-J., Pacheco, Y., Perol, M., Lafanechere, L., Penet, A., Peiller, E.-L., and Dumontet, C. (2005) Expression of class III b-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clinical Cancer Research, 11, 5481-5486.
111. Mozzetti, S., Ferlini, C., Concolino, P., Filippetti, E., Raspaglio, G., Prislei, S., Gallo, D., Martinelli, E., Ranelletti, F.O., Ferrandina, G., and Scambia, G. (2005) Class III b-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clinical Cancer Research, 11, 298-305.
112. Nicoletti, M., Valoti, G., Giannakakou, P., Zhan, Z., Kim, J., Lucchini, V., Landoni, F., Mayo, J., Giavazzi, R., and Fojo, T. (2001) Expression of b-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-anticancer drug screen correlation with sensitivity to microtubule active agents. Clinical Cancer Research, 7, 2912-2922.
113. Han, H.K.-H., Gehrke, L., Tahir, S., Credo, R., Cherian, S., Sham, H., Rosenberg, S., and Ng, S. (2000) Modulation of drug resistance by a-tubulin in paclitaxel-resistant human cancer cell lines. European Journal of Cancer (Oxford, England: 1990), 36, 1565-1571.
114. Parness, J., Kingston, D.G.I., Powell, R.G., Harracksingh, C., and Horwitz, S.B. (1982) Structure-activity study of cytotoxicity and microtubule assembly by taxol and related taxanes. Biochemical and Biophysical Research Communications, 105, 1082-1089.
115. Mellado, W., Magri, N.F., Kingston, D.G.I., Garcia-Arenas, R., Orr, G.A., and Horwitz, S.B. (1984) Preparation and biological activity of taxol acetates. Biochemical and Biophysical Research Communications, 124, 329-336.
116. Guenard, D., Gueritte-Voegelein, F., and Potier, P. (1993) Taxol and Taxotere: discovery, chemistry, and structure-activity relationships. Accounts of Chemical Research, 26, 160-167.
117. 1: Science and Applications (ed. M. Suffness), CRC Press, New York, pp. 317-375.
118. Ojima, I., Kuduk, S.D., and Chakravarty, S. (1998) Recent advances in the medicinal chemistry of taxoid anticancer agents, in Advances in Medicinal Chemistry (eds B.E. Maryanoff and A.B. Reitz), JAI Press, Greenwich, CT, pp. 69-124.
119. Kingston, D.G. (2000) Recent advances in the chemistry of taxol. Journal of Natural Products, 63, 726-734.
120. Kingston, D.G., Jagtap, P.G., Yuan, H., and Samala, L. (2002) The chemistry of taxol and related taxoids. Fortschritte der Chemie Organischer Naturstoffe, 84, 53-225.
121. Ojima, I. and Das, M. (2009) Recent advances in the chemistry and biology of new generation taxoids. Journal of Natural Products, 72, 554-565.
122. Magri, N.F. and Kingston, D.G.I. (1988) Modified taxols: 4. Synthesis and biological activity of taxols modified in the C13 side chain. Journal of Natural Products, 51, 298-306.
123. Gueritte-Voegelein, F., Guenard, D., Lavelle, F., LeGoff, M.-T., Mangatal, L., and Potier, P. (1991) Relationships between the structure of taxol analogues and their antimitotic activity. Journal of Medicinal Chemistry, 34, 992-998.
124. Ojima, I., Duclos, O., Zucco, M., Bissery, M.-C., Combeau, C., Vrignaud, P., Riou, J.F., and Lavelle, F. (1994) Synthesis and structure-activity relationships of new antitumor taxoids: effects of cyclohexyl substitution at the C-3 and/or C-2 of Taxotere (Docetaxel). Journal of Medicinal Chemistry, 37, 2602-2608.
125. 0-(tert-butyl) 3-dephenyl analogs of paclitaxel and docetaxel. Journal of Medicinal Chemistry, 38, 3821-3828.
126. Boge, T.C., Wu, Z.-J., Himes, R.H., Vander Velde, D.G., and Georg, G.I. (1999) Conformationally restricted paclitaxel analogues: macrocyclic mimics of the "Hydrophobic Collapse" conformation. Bioorganic & Medicinal Chemistry Letters, 9, 3047-3052.
127. Ojima, I., Lin, S., Inoue, T., Miller, M.L., Borella, C.P., Geng, X., and Walsh, J.J. (2000) Macrocycle formation by ring-closing metathesis (RCM): application to the syntheses of novel macrocyclic taxoids. Journal of the American Chemical Society, 122, 5343-5353.
128. Ojima, I., Duclos, O., Dormán, G., Simonot, B., Prestwich, G.D., Rao, S., Lerro, K.A., and Horwitz, S.B. (1995) A new paclitaxel photoaffinity analog with a 3-(4-benzoylphenyl)propanoyl probe for characterization of drug-binding sites on tubulin and P-glycoprotein. Journal of Medicinal Chemistry, 38, 3891-3894.
129. 0 -and 7-benzophenone analogs of taxol in the carboxyl terminal half or murine mdr1b P-glycoprotein. Biochemistry, 37, 11272-11279.
130. Chordia, M.C., Kingston, D.G.I., Hamel, E., Lin, C.M., Long, B.H., Fairchild, C.A., Johnston, K.A., and Rose, W.C. (1997) Synthesis and biological activity of A-nor-paclitaxel analogues. Bioorganic & Medicinal Chemistry, 5, 941-947.
131. 1. The Journal of Organic Chemistry, 59, 515-517.
132. Georg, G.I., Ali, S.M., Boge, T.C., Datta, A., Falborg, L., Park, H., Mejillano, M., and Hirnes, R.H. (1995) Synthesis of biologically active 2-benzoyl paclitaxel analogues. Bioorganic & Medicinal Chemistry Letters, 5, 259-264.
133. Chordia, M.D., Yuan, H., Jagtap, P.G., Kadow, J.F., Long, B.H., Fairchild, C.R., Johnstonc, K.A., and Kingston, D.G.I. (2001) Synthesis and bioactivity of 2,4-diacyl analogues of paclitaxel. Bioorganic & Medicinal Chemistry, 9, 171-178.
134. Chaudhary, A.G., Gharpure, M.M., Rimoldi, J.M., Chordia, M.D., Gunatilaka, A.A.L., Kingston, D.G.I., Grover, S., Lin, C.M., and Hamel, E. (1994) Unexpectedly facile hydrolysis of the 2-benzoate group of taxol and syntheses of analogs with increased activities. Journal of the American Chemical Society, 116, 4097-4098.
135. Vander Velde, D.G., Georg, G.I., Grunewald, G.L., Gunn, C.W., and Mitscher, L.A. (1993) "Hydrophobic collapse" of taxol and Taxotere solution conformations in mixtures of water and organic solvent. Journal of the American Chemical Society, 1993, 11650-11651.
136. Matesanz, R., Barasoain, I., Yang, C.-G., Wang, L., Li, X., Ines, C.D., Coderch, C., Gago, F., Barbero, J., Andreu, J., Fang, W.-S., and Diaz, J. (2008) Optimization of taxane binding to microtubules: binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel. Chemistry & Biology, 15, 573-585.
137. Ojima, I., Slater, J.C., Michaud, E., Kuduk, S.D., Bounaud, P.-Y., Vrignaud, P., Bissery, M.C., Veith, J.M., Pera, P., and Bernacki, R.J. (1996) Syntheses and structure-activity relationships of the second-generation antitumor taxoids: exceptional activity against drug-resistant cancer cells. Journal of Medicinal Chemistry, 39, 3889-3896.
138. Kingston, D.G.I. (1998) Studies on the chemistry of taxol. Pure and Applied Chemistry, 70, 331-334.
139. Yuan, H., Fairchild, C.R., Liang, X., and Kingston, D.G.I. (2000) Synthesis and biological activity of C-6 and C-7 modified paclitaxels. Tetrahedron, 56, 6407-6414.
140. Wittman, M.D., Altstadt, T.J., Fairchild, C., Hansel, S., Johnston, K., Kadow, J.F., Long, B.H., Rose, W.C., Vyas, D.M., Wu, M.-J., and Zoeckler, M.E. (2001) Synthesis of metabolically blocked paclitaxel analogues. Bioorganic & Medicinal Chemistry Letters, 11, 809-810.
141. Yuan, H., Kingston, D.G.I., Sackett, D.L., and Hamel, E. (1999) Synthesis and biological activity of a novel C4-C6 bridged paclitaxel analog. Tetrahedron, 55, 9707-9716.
142. Roth, G.P., Marshall, D.R., and Chen, S.-H. (1995) Reaction of paclitaxel and 10-desacetyl baccatin III with diethylamino sulfurtrifluoride. Tetrahedron Letters, 36, 1609-1612.
143. Greenwald, R.B., Pendri, A., and Bolikal, D. (1995) Highly water soluble taxol derivatives: 7-polyethylene glycol carbamates and carbonates. The Journal of Organic Chemistry, 60, 331-336.
144. Altstadt, T.J., Fairchild, C.R., Golik, J., Johnston, K.A., Kadow, J.F., Lee, F.Y., Long, B.H., Rose, W.C., Vyas, D.M., Wong, H., Wu, M.-J., and Wittman, M.D. (2001) Synthesis and antitumor activity of novel C-7 paclitaxel ethers: discovery of BMS-184476. Journal of Medicinal Chemistry, 44, 4577-4583.
145. Metzger-Filho, O., Moulin, C., Azambuja, E.D., and Ahmad, A. (2009) Larotaxel: broadening the road with new taxanes. Expert Opinion on Investigational Drugs, 18, 1183-1189.
146. Chen, S.-H., Fairchild, C., Mamber, S.W., and Farina, V. (1993) Taxol structure-activity relationships: synthesis and biological evaluation of 10-deoxytaxol. The Journal of Organic Chemistry, 58, 2927-2928.
147. Ojima, I., Bounaud, P.-Y., and Ahern, D.G. (1999) New photoaffinity analogs of paclitaxel. Bioorganic & Medicinal Chemistry Letters, 9, 1189-1194.
148. Rao, S., He, L., Chakravarty, S., Ojima, I., Orr, G., and Horwitz, S. (1999) Characterization of the taxol binding site on the microtubule: identification of Arg282 in b-tubulin as the site of photoincorporation of a 7-benzophenone analogue of taxol. The Journal of Biological Chemistry, 274, 37990-37994.
149. Appendino, G., Danieli, B., Jakupovic, J., Belloro, E., Seambia, G., and Bombardelli, E. (1997) Synthesis and evaluation of C-seco paclitaxel analogues. Tetrahedron Letters, 38, 4273-4276.
150. Ferlini, C., Raspaglio, G., Mozzetti, S., Cicchillitti, L., Filippetti, F., Gallo, D., Fattorusso, C., Campiani, G., and Scambia, G. (2005) The seco-taxane IDN5390 is able to target class III b-tubulin and to overcome paclitaxel resistance. Cancer Research, 65, 2397-2405.
151. Haber, M., Burkhart, C.A., Regl, D.L., Madafiglio, J., Norris, M.D., and Horwitz, S.B. (1995) Altered expression of M2, the class II-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. The Journal of Biological Chemistry, 270, 31269-31275.
152. Kavallaris, M., Burkhart, C.A., and Horwitz, S.B. (1999) Antisense oligonucleotides to class III b-tubulin sensitize drug-resistant cells to taxol. British Journal of Cancer, 80, 1020-1025.
153. Pepe, A., Sun, L., Zanardi, I., Wu, X., Ferlini, C., Fontana, G., Bombardelli, E., and Ojima, I. (2009) Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III b-tubulin. Bioorganic & Medicinal Chemistry Letters, 19, 3300-3304.
154. Wang, M., Cornett, B., Nettles, J., Liotta, D.C., and Snyder, J.P. (2000) The oxetane ring in taxol. The Journal of Organic Chemistry, 65, 1059-1068.
155. Barboni, L., Datta, A., Dutta, D., Georg, G.I., Vander Velde, D.G., Himes, R.H., Wang, M., and Snyder, J.P. (2001) Novel D-seco paclitaxel analogues: synthesis, biological evaluation and model testing. The Journal of Organic Chemistry, 66, 3321-3329.
156. Samaranayake, G., Magri, N.F., Jitrangsri, C., and Kingston, D.G.I. (1991) Modified taxols: 5. Reaction of taxol with electrophilic reagents and preparation of a rearranged taxol derivative with tubulin assembly activity. The Journal of Organic Chemistry, 56, 5114-5119.
157. Marder-Karsenti, R., Dubois, J., Bricard, L., Guenard, D., and Gueritte-Voegelein, F. (1997) Synthesis and biological evaluation of D-ring-modified taxanes: 5(20)-azadocetaxel analogs. The Journal of Organic Chemistry, 62, 6631-6637.
158. Gunatilaka, A.A.L., Ramdayal, F.D., Sarragiotto, M.H., and Kingston, D.G.I. (1999) Synthesis and biological evaluation of novel paclitaxel (taxol) D-ring modified analogues. The Journal of Organic Chemistry, 64, 2694-2703.
159. Dubois, J., Thoret, S., Gueritte, F., and Guenard, D. (2000) Synthesis of 5(20) deoxydocetaxel, a new active docetaxel analogue. Tetrahedron Letters, 41, 3331-3334.
160. Deutsch, H.M., Glinski, J.A., Hernandez, M., Haugwitz, R.D., Narayanan, V.L., Suffness, M., and Zalkow, L.H. (1989) Synthesis of congeners and prodrugs: 3. Water-soluble prodrugs of taxol with potent antitumor activity. Journal of Medicinal Chemistry, 32, 788-792.
161. Nicolaou, K.C., Dai, W.-M., and Guy, R.K. (1994) Chemistry and biology of taxol. Angewandte Chemie -International Edition in English, 33, 15-44.
162. Safavy, A., Raisch, K.P., Khazaeli, M.B., Buchsbaum, D.J., and Bonner, J.A. (1999) Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. Journal of Medicinal Chemistry, 42, 4919-4924.
163. Paradis, R. and Page, M. (1998) New active paclitaxel glucuronide derivative with improved water solubility. International Journal of Oncology, 12, 391-395.
164. Pendri, A., Conover, C.D., and Greenwald, R.B. (1998) Antitumor activity of paclitaxel-2-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug. Anti-Cancer Drug Design, 13, 387-395.
165. Dosio, F., Arpicco, S., Brusa, P., Stella, B., and Cattel, L. (2001) Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: preparation, characterization and pharmacokinetics. Journal of Controlled Release, 76, 107-117.
166. Niethammer, A., Gaedicke, G., Lode, H.N., and Wrasidlo, W. (2001) Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility. Bioconjugate Chemistry, 12, 414-420.
167. 1), mitomycin C and doxorubicin. Bioorganic & Medicinal Chemistry Letters, 8, 3347-3352.
168. 1 and analogues determined by NMR spectroscopy and molecular modeling studies. Tetrahedron, 49, 6533-6544.
169. Gueritte-Voegelein, F., Guenard, D., Mangatal, L., Potier, P., Guilhem, J., Cesario, M., and Pascard, C. (1990) Structure of a synthetic taxol precursor: N-tert-butoxycarbonyl-10-deacetyl-N-debenzoyltaxol. Acta Crystallographica, C46, 781-784.
170. 3 solution from nOe Data: 2D NMR ROESY buildup rates at 500MHz. Journal of Natural Products, 55, 1157-1161.
171. Kingston, D., Bane, S., and Snyder, J. (2005) The taxol pharmacophore and the T-taxol bridging principle. Cell Cycle (Georgetown, Tex.), 4, 279-289.
172. Ojima, I., Kuduk, S.D., Chakravarty, S., Ourevitch, M., and Bégué, J.-P. (1997) A novel approach to the study of solution structures and dynamic behavior of paclitaxel and docetaxel using fluorine-containing analogs as probes. Journal of the American Chemical Society, 119, 5519-5527.
173. Nogales, E., Wolf, S.G., and Downing, K.H. (1998) Structure of the ab tubulin dimer by electron crystallography. Nature, 391, 199-203.
174. 0 -(p-Azidobenzamido)taxol photolabels the N-terminal 31 amino acids of b-tubulin. The Journal of Biological Chemistry, 269, 3132-3134.
175. Rao, S., Orr, G.A., Chaudhary, A.G., Kingston, D.G.I., and Horwitz, S.B. (1995) Characterization of the taxol binding site on the microtubule: 2-(m-azidobenzoyl) taxol photolabels a peptide (amino acids 217-231) of b-tubulin. The Journal of Biological Chemistry, 270, 20235-20238.
176. Li, Y., Poliks, B., Cegelski, L., Poliks, M., Gryczynski, Z., Piszczek, G., Jagtap, P., Studelska, D., Kingston, D., Schaefer, J., and Bane, S. (2000) Conformation of microtubule-bound paclitaxel determined by fluorescence spectroscopy and REDOR NMR. Biochemistry, 39, 281-291.
177. Paik, Y., Yang, C., Metaferia, B., Tang, S., Bane, S., Ravindra, R., Shanker, N., Alcaraz, A., Johnson, S., Schaefer, J., O'Connor, R., Cegelski, L., Snyder, J., and Kingston, D. (2007) REDOR NMR distance measurements for the tubulin-bound paclitaxel conformation. Journal of the American Chemical Society, 129, 361-370.
178. Snyder, J., Nettles, J., Cornett, B., Downing, K., and Nogales, E. (2001) The binding conformation of taxol in b-tubulin: a model based on electron crystallographic density. Proceedings of the National Academy of Sciences of the United States of America, 98, 5312-5316.
179. Geney, R., Sun, L., Pera, P., Bernack, R., Xia, S., Horwitz, S., Simmerling, C., and Ojima, I. (2005) Use of the tubulin-bound paclitaxel conformation for structure-based rational drug design. Chemistry & Biology, 12, 339-348.
180. Alcaraz, A.A., Mehta, A.K., Johnson, S.A., and Snyder, J.P. (2006) The T-taxol conformation. Journal of Medicinal Chemistry, 49, 2478-2488.
181. Sun, L., Simmerling, C., and Ojima, I. (2009) Recent advances in the study of the bioactive conformation of taxol. ChemMedChem, 4, 719-731.
182. Ganesh, T., Guza, R.C., Bane, S., Ravindra, R., Shanker, N., Lakdawala, A.S., Snyder, J.P., and Kingston, D.G.I. (2004) The bioactive taxol conformation on b-tubulin: experimental evidence from highly active constrained analogs. Proceedings of the National Academy of Sciences of the United States of America, 101, 10006-10011.
183. 0 bridged paclitaxel analogues. Journal of Medicinal Chemistry, 50, 713-725.
184. 0BzN-linked macrocyclic taxoids. The Journal of Organic Chemistry, 73, 9584-9593.
185. Gullion, T. and Schaefer, J. (1989) Rotational-echo double-resonance NMR. Journal of Magnetic Resonance (San Diego, Calif: 1997), 81, 196-200.
186. Lowe, J., Li, H., Downing, K.H., and Nogales, E. (2001) Refined structure of a,b-tubulin at 3.5 Ao resolution. Journal of Molecular Biology, 313, 1045-1057.
187. Diaz, J., Barasoain, I., and Andreu, J. (2003) Fast kinetics of taxol binding to microtubules: effects of solution variables and microtubule-associated proteins. The Journal of Biological Chemistry, 278, 8407-8419.
188. Buey, R., Calvo, E., Barasoain, I., Pineda, O., Edler, M., Matesanz, R., Cerezo, G., Vanderwal, C., Day, B., Sorensen, E., Lopez, J., Andeu, J., Hamel, E., and Diaz, J. (2007) Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites. Nature Chemical Biology, 3, 117-125.
189. Buey, R., Diaz, J., Andreu, J., O'Brate, A., Giannakakou, P., Nicolaou, K., Sasmal, P., Ritzen, A., and Namoto, K. (2004) Interaction of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, microtubule stabilization and cytotoxicity. Chemistry & Biology, 11, 225-236.
190. Lage, H. and Dietel, M.J. (2002) Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells. Journal of Cancer Research and Clinical Oncology, 128, 349-357.
191. O'Driscoll, L., Walsh, N., Larkin, A., Ballot, J., Ooi, W.S., Gullo, G., O'Connor, R., Clynes, M., Crown, J., and Kennedy, S. (2007) MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma. Anticancer Research, 27, 2115-2120.
192. 0 -dephenyldocetaxels. Bioorganic & Medicinal Chemistry Letters, 4, 2631-2634.
193. Ojima, I., Kuduk, S.D., Pera, P., Veith, J.M., and Bernacki, R.J. (1997) Synthesis and structure-activity relationships of non-aromatic taxoids: effects of alkyl and alkenyl ester groups on cytotoxicity. Journal of Medicinal Chemistry, 40, 279-285.
194. Ojima, I., Wang, T., Miller, M.L., Lin, S., Bollera, C.P., Geng, X., Pera, P., and Bernacki, R.J. (1999) Synthesis and structure-activity relationships of new second-generation taxoids. Bioorganic & Medicinal Chemistry Letters, 9, 3423-3428.
195. Ojima, I., Chen, J., Sun, L., Borella, C.P., Wang, T., Miller, M.L., Lin, S., Geng, X., Kuznetsova, L., Qu, C., Gallager, D., Zhao, X., Zanardi, I., Xia, S., Horwitz, S.B., Mallen-St. Clair, J., Guerriero, J.L., Bar-Sagi, D., Veith, J.M., Pera, P., Bernacki, R.J. (2008) Design, synthesis, and biological evaluation of new-generation taxoids. Journal of Medicinal Chemistry, 51, 3203-3221.
196. Ojima, I., Park, Y.H., Fenoglio, I., Duclos, O., Sun, C.-M., Kuduk, S.D., Zucco, M., Appendino, G., Pera, P., Veith, J.M., Bernacki, R.J., Bissery, M.-C., Combeau, C., Vrignaud, P., Riou, J.F., and Lavelle, F. (1995) Syntheses and structure-activity relationships of new taxoids, in Taxane Anticancer Agents: Basic Science and Current Status, ACS Symposium Series 583 (eds G.I. Georg, T.T. Chen, I. Ojima, and D.M. Vyas), American Chemical Society, Washington, DC, pp. 262-275.
197. Ferlini, C., Distefano, M., Pignatelli, F., Lin, S., Riva, A., Bombardelli, E., Mancuso, S., Ojima, I., and Scambia, G. (2000) Antitumor activity of novel taxanes that act as cytotoxic agents and P-glycoprotein inhibitors at the same time. British Journal of Cancer, 83, 1762-1768.
198. Yamazaki, T., Taguchi, T., and Ojima, I. (2009) Unique properties of fluorine and their relevance to medicinal chemistry and chemical biology, in Fluorine in Medicinal Chemistry and Chemical Biology (ed. I. Ojima), Wiley-Blackwell, Chichester, pp. 3-46.
199. 0-trifluoromethyl-taxoids. Journal of Fluorine Chemistry, 129, 817-828.
200. 0 -difluoromethyl-taxoids. Bioorganic & Medicinal Chemistry Letters, 8, 1619-1628.
201. 0-trifluoromethyl taxoids. Bioorganic & Medicinal Chemistry Letters, 7, 133-138.
202. Gut, I., Ojima, I., Vaclavikova, R., Simek, P., Horsky, S., Soucek, P., Kondrova, E., Kuznetsova, L.V., and Chen, J. (2006) Metabolism of new-generation taxanes in human, pig, minipig and rat liver microsomes. Xenobiotica; The Fate of Foreign Compounds in Biological Systems, 36, 772-792.
203. Ojima, I., Kuznetsova, L., and Sun, L. (2007) Organofluorine chemistry at the biomedical interface: a case study on fluoro-taxoid anticancer agents, in Current Fluoroorganic Chemistry: New Synthetic Directions, Technologies, Materials and Biological Applications, ACS Symposium Series 949 (eds V. Soloshonok, K. Mikami, T. Yamazaki, J.T. Welch, and J. Honek), American Chemical Society/Oxford University Press, Washington, DC, pp. 288-304.
204. 0 -difluorovinyl taxoids. Journal of Fluorine Chemistry, 143, 177-188.
205. Ehrlichová, E., Ojima, I., Václavíková, R., Němcová-Fürstová, V., Vobořilová, J., Šimek, P., Horský, S., Souček, P., Kovář, J., and Gut, I. (2012) Transport, metabolism, cytotoxicity and effects of novel taxanes on the cell cycle in MDA-MB-435 and NCI/ ADR-RES cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 385, 1035-1048.
206. Appendino, G., Gariboldi, P., Gabetta, B., Pace, R., Bombardelli, E., and Viterbo, D. (1992) 14b-Hydroxy-l0-deacetylbaccatin III, a new taxane from Himalayan yew (Taxus wallichiana Zucc.). Journal of the Chemical Society, Perkin Transactions 1, 2925-2929.
207. Ojima, I., Slater, J.C., Kuduk, S.D., Takeuchi, C.S., Gimi, R.H., Sun, C.-M., Park, Y.H., Pera, P., Veith, J.M., and Bernacki, R.J. (1997) Syntheses and structure-activity relationships of taxoids derived from 14b-hydroxy-10-deacetylbaccatin III. Journal of Medicinal Chemistry, 40, 267-278.
208. Ojima, I., Fenoglio, I., Park, Y.H., Pera, P., and Bernacki, R.J. (1994) Synthesis and biological activity of 14b-hydroxydocetaxel. Bioorganic & Medicinal Chemistry Letters, 4, 1571-1574.
209. Ojima, I., Park, Y.H., Sun, C.-M., Fenoglio, I., Appendino, G., Pera, P., and Bernacki, R.J. (1994) Structure-activity relationships of new taxoids derived from 14b-hydroxy-10-deacetylbaccatin III. Journal of Medicinal Chemistry, 37, 1408-1410.
210. Gunawardana, G., Premachandran, U., Burres, N.S., Whitten, D., Henry, R., Spanton, S., and McAlpine, J.B. (1992) Isolation of 9-dihydro-13-acetylbaccatin III from Taxus canadensis. Journal of Natural Products, 55, 1686-1689.
211. Zamir, L.O., Nedea, M.E., Belair, S., Sauriol, F., Mamer, O., Jacqmain, E., Jean, F.I., and Carneau, F.X. (1992) Taxanes isolated from Taxus canadensis. Tetrahedron Letters, 33, 5173-5176.
212. Ishiyama, T., Iimura, S., Ohsuki, S., Uoto, K., Terasawa, H., and Soga, T. (2002) New highly active taxoids from 9b-dihydrobaccatin-9,10-acetals. Bioorganic & Medicinal Chemistry Letters, 12, 1083-1086.
213. Takeda, Y., Uoto, K., Chiba, J., Horiuchi, T., Iwahana, M., Atsumi, R., Ono, C., Terasawab, H., and Soga, H. (2003) New highly active taxoids from 9b-dihydrobaccatin-9,10-acetals: Part 4. Bioorganic & Medicinal Chemistry, 11, 4431-4447.
214. Takeda, Y., Yoshinoa, T., Uoto, K., Chiba, J., Ishiyama, T., Iwahana, M., Jimbo, T., Tanaka, N., Terasawa, H., and Soga, T. (2003) New highly active taxoids from 9b-dihydrobaccatin-9,10-acetals: Part 3. Bioorganic & Medicinal Chemistry Letters, 13, 185-190.
215. Takeda, Y., Uoto, K., Iwahana, M., Jimbo, T., Nagata, M., Atsumi, R., Ono, C., Tanaka, N., Terasawa, H., and Soga, T. (2004) New highly active taxoids from 9b-dihydrobaccatin-9,10-acetals: Part 5. Bioorganic & Medicinal Chemistry Letters, 21, 3209-3215.
216. Shionoya, M., Jimbo, T., Kitagawa, M., Soga, T., and Tohgo, A. (2003) DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Science, 94, 459-466.
217. Verweij, J., Clavel, M., and Chevalier, B. (1994) Paclitaxel (taxol) and docetaxel (Taxotere): not simply two of a kind. Annals of Oncology, 5, 495-505.
218. Valero, V., Jones, S.E., vonHoff, D.D., Booser, D.J., Mennel, R.G., Ravdin, P.M., Holmes, F.A., Rahman, Z., Schottstaedt, M.W., Erban, J.K., Esparza-Guerra, L., Earhart, R.H., Hortobagyi, G.N., and Burris, H.A., III (1998) A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. Journal of Clinical Oncology, 16, 3362-3368.
219. Verschraegen, C., Sittisomwong, T., Kudelka, A., Guedes, E., Steger, M., Nelson-Taylor, T., Vincent, M., Rogers, R., Atkinson, E., and Kavanagh, J. (2000) Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. Journal of Clinical Oncology, 18, 2733-2739.
220. Bissery, M., Nohynek, G., Sanderink, G., and Lavelle, F. (1995) Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anti-Cancer Drugs, 6, 339-355.
221. Tomiak, E., Piccart, M., Kerger, J., Lips, S., Awada, A., Valeriola, D.D., Ravoet, C., Lossignol, D., Sculier, J., and Auzannet, V. (1994) Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. Journal of Clinical Oncology, 12, 1458-1467.
222. Oosterom, A.V., Schrijvers, D., and Schrijvers, D. (1995) Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: clinical experience. Anti-Cancer Drugs, 6, 356-368.
223. Ravdin, R., Burris, H.A. III, Cook, G., Eisenberg, P., Kane, M., Bierman, W., Mortimer, J., Genevois, E., and Bellet, R. (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. Journal of Clinical Oncology, 13, 2879-2885.
224. Valero, V., Holmes, F., Walters, R., Theriault, R., Esparza, L., Fraschini, G., Fonseca, G., Bellet, R., Buzdar, A., and Hortobagyi, G. (1995) Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. Journal of Clinical Oncology, 13, 2886-2894.
225. Chevallier, B., Fumoleau, P., Kerbrat, P., Dieras, V., Roche, H., Krakowski, I., Azli, N., Bayssas, M., Lentz, M., and Glabbeke, M.V. (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the clinical screening cooperative group of the European organization for research and treatment of cancer. Journal of Clinical Oncology, 13, 314-322.
226. Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J., Weaver, C., Tomiak, E., Al-Tweigeri, T., Chap, L., Juhos, E., Guevin, R., Howell, A., Fornadnder, T., Hainsworth, J., Coleman, R., Winholes, J., Modiano, M., Pinter, T., Tang, S., Colwell, B., Prady, C., Provencher, L., Walde, D., Rodriguez-Lescure, A., Hugh, J., Loret, C., Rupin, M., Blitz, S., Jacovs, P., Murawsky, M., Riva, A., and Vogel, C. (2005) Adjuvant docetaxel for node-positive breast cancer. New England Journal of Medicine, 352, 2302-2312.
227. Cutsem, E.V., Moiseyenko, V., Tjulandin, S., Majlis, A., Constenla, M., Boni, B., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., Risse, M.-L., and Ajani, J. (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. Journal of Clinical Oncology, 24, 4991-4997.
228. Fossella, R., DeVore, R., Kerr, R., Crawford, J., Natale, R., Dunphy, F., Kalman, L., Miller, V., Lee, J., Moore, M., Gandara, D., Karp, D., Vokes, E., Kris, M., Kim, Y., Gamza, F., and Hammershaimb, L. (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. Journal of Clinical Oncology, 18, 2354-2362.
229. Fossella, F., Pereira, J., Pawel, J.V., Pluzanska, A., Gorbounova, V., Kaukel, E., Mattson, K., Ramlau, R., Szczesna, A., Fidias, P., Millward, M., and Belani, C. (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology, 21, 3016-3024.
230. Dagher, R., Li, N., Abraham, S., Rahman, A., Sridhara, R., and Pazdur, R. (2004) Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clinical Cancer Research, 10, 8147-8151.
231. Vermorken, J., Remenar, E., Herpen, C.V., Gorila, T., Mesia, R., Degardin, M., Stewart, J., Jelic, S., Betka, J., Preiss, J., Weyndaert, D.V.D., Awada, A., Cupissol, D., Kienzer, H., Rey, A., Desaunois, I., Bernier, J., and Lefebvre, J.-L. (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. The New England Journal of Medicine, 357, 1695-1704.
232. Tannock, I., Wit, R.D., Berry, W., Horti, J., Pluzanska, A., Chi, K., Oudard, S., Theodore, C., James, N., Turesson, I., Rosenthal, M., and Eisenberger, M. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England Journal of Medicine, 351, 1502-1512.
233. Hugh, J., Hanson, H., Cheang, M., Nielsen, T., Perou, C., Dumontet, C., Reed, J., Krajewska, M., Treilleux, I., Rupin, M., Manherini, E., Mackey, J., Martin, M., and Vogel, C. (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. Journal of Clinical Oncology, 27, 1168-1176.
234. Montero, A., Fossella, F., Hortobagyi, G., and Valero, V. (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. The Lancet Oncology, 6, 229-239.
235. Laurentiis, M.D., Cancello, G., Dágostino, D., Giuliano, M., Giordano, A., Monagna, E., Lauria, R., Forestieri, V., Esposito, A., Silvestro, L., Pennacchio, R., Cricitiello, C., Montanino, A., Limite, G., Bianco, A., and Placido, S.D. (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. Journal of Clinical Oncology, 26, 44-53.
236. Esteva, F., Valero, V., Booser, D., Guerra, L., Murray, J., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fitsche, H., Sneige, N., Smith, T., and Hortobagyi, G. (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. Journal of Clinical Oncology, 20, 1800-1808.
237. Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Anton, A., Lluch, A., Kennedy, J., O'Byrne, K., Conte, P., Green, M., Ward, C., Mayne, K., and Extra, J.-M. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Journal of Clinical Oncology, 23, 4265-4274.
238. Valero, V., Forbes, J., Pegram, M., Pienkowski, T., Eiermann, W., Minckwitz, G.V., Roche, H., Martin, M., Crown, J., Mackey, J., Fumoleau, P., Rolski, J., Mrsic-Krmpotic, Z., Jagiello-Gruszfeld, A., Riva, A., Buyse, M., Taupin, H., Sauter, G., Press, M., and Slamon, D. (2011) Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. Journal of Clinical Oncology, 29, 149-156.
239. Valero, V., Slamon, D., Wiermann, W., Robert, N., Pienkowski, T., Martin, M., Mackey, J., Lindsay, M., Bee-Munteanu, V., Press, M., Sauter, G., and Crown, J. (2011) Efficacy results of node-negative HER2-amplified breast cancer subset from BCIRG 006 study: a phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin, and trastuzumab (TCH). Journal of Clinical Oncology, 29, s553.
240. Joensuu, H., Bono, P., Kataja, V., Alanko, T., Kokko, R., Asola, R., Utriainen, T., Turpeenniemi-Hujanen, T., Jyrkkio, S., Moykkynen, K., Helle, L., Ingalsuo, S., Pajunen, M., Huusko, M., Salminen, T., Auvinen, P., Leinonen, H., Leinonen, M., Isola, J., and Kellokumpu-Lehtinen, P.-L. (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. Journal of Clinical Oncology, 27, 5685-5692.
241. Smith, J., Buyse, M., Rastogi, P., Geyer, Jr. C., Jacobs, S., Patocskai, E., and Wolmark, N. (2009) Epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab and bevacizumab as neoadjuvant therapy for HER2-positive locally advanced breast cancer (LABC) or as adjuvant therapy for HER2-positive pathologic stage III breast cancer (PS3BC): a phase II trial of the SNABP Foundation Research Group. Journal of Clinical Oncology, 27, s580.
242. Miles, D., Chan, A., Dirix, L., Cortes, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J., Provencher, L., Puglisi, F., Harbeck, N., Steger, G., Schneeweiss, A., Wardley, A., Chlistalla, A., and Romieu, G. (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology, 28, 3239-3247.
243. Pfister, D., Johnson, D., Azzoli, C., Sause, W., Smith, T., Baker, Jr. B., Olak, J., Stover, D., Strawn, J., Turrisi, A., and Somerfield, M. (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. Journal of Clinical Oncology, 22, 330-353.
244. Davies, A.M., Lara, Jr. P.N., Mack, P.C., and Gandara, D.R. (2003) Docetaxel in non-small cell lung cancer: a review. Expert Opinion on Pharmacotherapy, 4, 553-565.
245. Ishimoto, O., Sakakibara, T., Maemondo, M., Inoue, A., Matsubara, N., Morikawa, N., Okudera, K., Usui, K., Suzuki, T., Nukiwa, T., and Sugawara, S. (2012) S-1 combined with bi-weekly docetaxel for non-small cell lung cancer previously treated with platinum-based chemotherapy: a phase II study of North Japan Lung Cancer Group (NJLCG0701). Cancer and Clinical Oncology, 1, 108-117.
246. Herbst, R., Sun, Y., Eberhardt, W., Germonpre, P., Saijo, N., Zhou, V., Wang, J., Li, L., Kabbinavar, F., Ichinose, Y., Qin, S., Zhang, L., Biesma, B., Heymach, J., Langmuir, P., Kennedy, S., Tada, H., and Johnson, B. (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. The Lancet Oncology, 11, 619-626.
247. Berthold, D., Pond, G., Soban, F., Wit, R.D., Eisenberger, M., and Tannock, I. (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Journal of Clinical Oncology, 26, 242-245.
248. Oh, W., Febbo, P., Richie, J., Fennessy, F., Scibelli, G., Hayes, J., Choueiri, T., Tempany, C., Taplin, M., and Ross, R. (2009) A phase II study of neoadjuvant chemotherapy with docetaxel and bevacizumab in patients (pts) with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium Trial. Journal of Clinical Oncology, 27, s5060.
249. Reid, A.H., Attard, G., Danila, D.C., Oommen, N.B., Olmos, D., Fong, P.C., Molife, L.R., Hunt, J., Messiou, C., Parker, C., Dearnaley, D., Swennenhuis, J.F., Terstappen, L.W., Lee, G., Kheoh, T., Molina, A., Ryan, C.J., Small, E., Scher, H.I., and deBono, J.S. (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. Journal of Clinical Oncology, 28, 1489-1495.
250. de Bono, J.S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J., Shen, L., Matthews, P., and Sartor, A. (2010) Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC). Journal of Clinical Oncology, 28, s4508.
251. Tetzlaff, E., Cheng, J., and Ajani, J. (2008) Review of docetaxel in the treatment of gastric cancer. Therapeutics and Clinical Risk Management, 4, 999-1007.
252. Sun, W., Powell, M., O'Dwyer, P.J., Catalano, P., Ansari, R.H., and Benson, A.B. III (2010) Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. Journal of Clinical Oncology, 28, 2947-2951.
253. Enzinger, P., Ryan, D., Clark, J., Muzikansky, A., Earle, C., Kulke, M., Meyerhardt, J., Blaszkowsky, L., Zhu, A., Fidias, P., Vincitore, M., Mayer, R., and Fuchs, C. (2009) Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Annals of Oncology, 20, 475-480.
254. Kelsen, D., Jhawer, M., Ilson, D., Tse, A., Randazzo, J., Robinson, E., Capanu, M., and Shah, M. (2009) Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: results of a phase II clinical trial. Journal of Clinical Oncology, 27, s4512.
255. Shah, M., Jhawer, M., Ilson, D., Lefkowitz, R., Robinson, E., Capanu, M., and Kelsen, D. (2011) Phase II study of modified docetaxel, cisplatin, and fluororuacil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. Journal of Clinical Oncology, 29, 868-874.
256. Enzinger, P., Ryan, D., Regan, E., Lehman, N., Abrams, T., Hezel, A., Fidias, P., Sequist, L., Blaszkowsky, L., and Fuchs, C. (2008) Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. Journal of Clinical Oncology, 26, s4552.
257. El-Rayes, B., Zalupski, M., Bekai-Saab, T., Heilbrun, L., Hammad, N., Patel, B., Urba, S., Shields, A., Vaishampayan, U., Dawson, S., Almhanna, K., Smith, D., and Philip, P. (2010) A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Annals of Oncology, 21, 1999-2004.
258. Posner, M.R., Hershock, D.M., Blajman, C.R., Mickiewicz, E., Winguist, E., Gorbounova, V., Tjulandin, S., Shin, D.M., Cullen, K., Ervin, T.J., Murphy, B.A., Raez, L.E., Cohen, R.B., Spaulding, M., Tishler, R.B., Roth, B., Viroglio, R.C., Venkatesan, V., Romanov, I., Agarwala, S., Harter, K.W., Dugan, M., Cmelak, A., Markoe, A.M., Read, P.W., Steinbrenner, L., Colevas, A.D., Norris, Jr. C.M., and Haddad, R.I. (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. The New England Journal of Medicine, 357, 1705-1715.
259. Lorch, J., Goloubeva, O., Haddad, R., Cullen, K., Sarlis, N., Tishler, R., Tan, M., Fasciano, J., Sammartino, D., and Posner, M. (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. The Lancet Oncology, 12, 153-159.
260. Vasey, P., Jayson, G., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., Parkin, D., Paul, J., Hay, A., and Kaye, S. (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. Journal of the National Cancer Institute, 96, 1682-1691.
261. Pokrzywinski, R., Secord, A., Havrilesky, L., Puls, L., Holloway, R., Lewandowski, G., Higgins, R., Nycum, L., Kohler, M., and Revicki, D. (2011) Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial. Gynecologic Oncology, 123, 505-510.
262. Secord, A., Berchuck, A., Higgins, R., Nycum, L., Kohler, M., Puls, L., Holloway, R., Lewandowski, G., Valea, F., and Havrilesky, L. (2012) A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Cancer, 118, 3283-3293.
263. Fu, S., Hennessy, B.T., Ng, C.S., Ju, Z., Coombes, K.R., Wolf, J.K., Sood, A.K., Levenback, C.F., Coleman, R.L., Kavanagh, J.J., Gershenson, D.M., Markman, M., Dice, K., Howard, A., Li, J., Li, Y., Stemke-Hale, K., Dyer, M., Atkinson, E., Jackson, E., Kundra, V., Kurzrock, R., Bast, Jr. R.C., and Mills, G.B. (2012) Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecologic Oncology, 126, 47-53.
264. Awada, A., Mano, M., Hendlisz, A., and Piccart, M. (2004) New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective. Expert Review of Anticancer Therapy, 4, 53-60.
265. Mita, A., Denis, L., Rowinsky, E., Bono, J.D., Goetz, A., Ochoa, L., Forouzesh, B., Beeram, M., Patnaik, A., Molpus, K., Semiond, D., Besenval, M., and Tolcher, A. (2009) Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clinical Cancer Research, 15, 723-730.
266. Tao, C.-K., Seng, S., Oh, W., and Galsky, M. (2011) Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. Clinical Medicine Insights: Oncology, 5, 163-169.
267. Bono, J.D., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M., Roessner, L.S.M., Gupta, S., and Sartor, A. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet, 376, 1147-1154.
268. Galsky, M., Dritselis, A., Kirkpatrick, P., and Oh, W. (2010) Cabazitaxel. Nature Reviews. Drug Discovery, 9, 677-678.
269. Pivot, X., Koralewski, P., Hidalgo, J., Chan, A., Goncalves, A., Schwartsmann, G., Assadourian, S., and Lotz, J. (2008) A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Annals of Oncology, 19, 1547-1552.
270. Besse-Hammer, T., Villanueva, C., Campone, M., Machiels, J., Awada, A., Magherini, E., Dubin, F., Semiond, D., and Pivot, X. (2009) A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy. Journal of Clinical Oncology, 27, s1053.
271. Villanueva, C., Awada, A., Campone, M., Machiels, J., Besse, T., Magherini, E., Dubin, F., Semiond, D., and Pivot, X. (2011) A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. European Journal of Cancer (Oxford, England: 1990), 47, 1037-1045.
272. Sessa, C., Cuvier, C., Caldiera, S., Bauer, J., Bosch, S.V.D., Monnerat, C., Semiond, D., Perard, D., Lebecq, A., Besenval, M., and Marty, M. (2002) Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Annals of Oncology, 13, 1140-1150.
273. Kurata, T., Shimada, Y., Tamura, T., Yamamoto, N., Hyodo, I., Saeki, T., Takashima, S., Fujiwara, K., Wakasugi, H., and Kashimura, M. (2000) Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors. Journal of Clinical Oncology, 18, 3164-3171.
274. Vernillet, L., Semiond, D., Vergniol, J., Pasquier, O., Dieras, V., Marty, M., Sessa, C., Gelmon, K., Latreille, J., Pazdur, R., and Besenval, M. (1998) Pharmacokinetics of a new taxoid (RPR 109881A): comparison of five different administration schedules. Proceedings: American Society of Clinical Oncology, 16, a749.
275. Dieras, V., Limantani, S., Lortholary, A., Tubiana-Hulin, M., Ferrero, J.-M., Minckwitz, F.V., Valero, V., Dreiling, L., Besenval, M., and Pouillart, P. (2003) A multicentre, non randomized phase II study with RPR 109881A in metastatic breast cancer (MBC) patients (pts). Proceedings: American Society of Clinical Oncology, 22, Abstract 565.
276. Dieras, V., Limentani, S., Romieu, G., Tubiana-Huli, M., Lortholary, A., Kaufman, P., Girre, V., Besenval, M., and Valero, V. (2008) Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Annals of Oncology, 19, 1255-1260.
277. Dieras, V., Viens, P., Veyret, C., Romieu, G., Awada, A., Lidbrink, E., Bonnefoi, H., Mery-Mignard, D., Dalenc, F., and Roche, H. (2008) Larotaxel (L) in combination with trastuzumab in patients with HER2{thorn} metastatic breast cancer (MBC): interim analysis of an open phase II label study. Journal of Clinical Oncology, 26, 1070.
278. Zatloukal, P., Gervais, R., Vansteenkiste, J., Bosquee, L., Sessa, C., Brain, E., Dansin, E., Urban, T., Dohollou, N., Besenval, M., and Quoix, E. (2008) Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIB or stage IV non-small cell lung cancer. Journal of Thoracic Oncology, 3, 894-901.
279. Robert, F., Harper, K., Ackerman, J., and Gupta, S. (2010) A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 65, 227-234.
280. Minderman, H., Brooks, T., Loughlin, K., Ojima, I., Bernacki, R., and Baer, M. (2004) Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 598862) and tRA96023. Cancer Chemotherapy and Pharmacology, 53, 363-369.
281. Creaven, P., Eckhardt, S., Hamm, J., Schwartz, G., Sutton, J., Kaidbey, J., Lathia, C., Bernacki, R., and Ramnath, N. (2002) Phase I and pharmacokinetic study of a novel taxane BAY-59-8862. Proceedings: American Society of Clinical Oncology, 21, a100.
282. Laurence, V., Pierga, J.-Y., Beuzeboc, P., Piperno-Neumann, S., Landon, F., Grange, V., Barouki, F., Brendel, E., Schwartz, B., and Dieras, V. (2003) A phase I and pharmacokinetic study of a novel taxane BAY 59-8862 with a weekly schedule. Proceedings: American Society of Clinical Oncology, 22, a647.
283. Gurtler, J., Pawel, J., Spiridonidis, C., Grossi, F., Larriba, J., Moscovici, M., Markovitz, E., Voliotis, D., and Gottfried, M. (2004) An uncontrolled phase II study evaluating anti-tumor efficacy and safety of ortataxel (BAY 59-8862) in patients with taxane-resistant non-small cell lung cancer. Journal of Clinical Oncology, 22, s7136.
284. Beer, M., Lenaz, L., and Amadori, D. (2008) Phase II study of ortataxel in taxane-resistant breast cancer. Journal of Clinical Oncology, 26, 1066.
285. Syed, S., Beeram, M., Takimoto, C., Jakubowitz, J., Kimura, M., Ducharme, M., Gadgeel, S., Jager, R.D., Rowinsky, E., and Lorusso, P. (2004) Phase I and pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (pts) with advanced cancers. Journal of Clinical Oncology, 22, s2028.
286. Evans, T., Dobrila, R., Berardi, R., Sumpter, K., Wall, L., Oyama, R., and Anthoney, D. (2006) A phase II study of DJ-927 as second-line therapy in patients (pts) with advanced gastric cancer (GC) who have failed a 5-FU non taxane based regimen. Journal of Clinical Oncology, 24, s4081.
287. Rhee, J., Lee, F., Saif, M., Ardalan, B., Wolff, R., Eng, C., Bogaard, K., Cheverton, P., Kimura, M., Danna, M., and Hoff, P. (2005) Phase II trial of DJ-927 as a second-line treatment for colorectal cancer demonstrates objective responses. Journal of Clinical Oncology, 23, s3654.
288. Moore, M., Jones, C., Harker, G., Lee, F., Ardalan, B., Saif, M., Hoff, P., Coomes, J., Rollins, C., and Felt, K. (2006) Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer. Journal of Clinical Oncology, 24, s3591.
289. Roche, M., Kyriakou, H., and Seiden, M. (2006) Drug evaluation: tesetaxel: an oral semisynthetic taxane derivative. Current Opinion in Investigational Drugs, 7, 1092-1099.
290. Baas, P., Szczesna, A., Albert, I., Milanowski, J., Juhasz, E., Sztancsik, Z., Pawel, J.V., Oyama, R., and Burgers, S. (2008) Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. Journal of Thoracic Oncology, 3, 745-750.
291. Beeram, M., Papadopoulos, K., Patnaik, A., Qureshi, A., and Tolcher, A. (2010) Phase I dose-ranging, pharmacokinetic (PK) study of tesetaxel, a novel orally active tubulin-binding agent. Journal of Clinical Oncology, 28, ae13075.
292. Beeram, M., Novick, S., Qureshi, A., Patnaik, A., Papadopoulos, K., and Tolcher, A. (2010) An intersubject dose-escalation study of tesetaxel administered orally once every 3 weeks and once weekly for 3 consecutive weeks in patients with advanced or metastatic solid tumors. Journal of Clinical Oncology, 28, 159.
293. Saif, M., Sarantopoulos, J., Patnaik, A., Tolcher, A., Takimoto, C., and Beeram, M. (2011) Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I dose-escalation study in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 68, 1565-1573.
294. Sampath, D., Discafani, C., Loganzo, F., Beyer, B., Liu, H., Tan, X., Musto, S., Annable, T., Gallagher, P., Rios, C., and Greenberger, L. (2000) MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Molecular Cancer Therapeutics, 2, 873-884.
295. Ramanathan, R., Picus, J., Raftopoulos, H., Bernard, S., Lockhart, A., Frenette, G., Macdonald, J., Melin, S., Berg, D., Brescia, F., Hochster, H., and Cohn, A. (2008) A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology, 61, 435-438.
296. Mekhail, T., Serwatowski, P., Dudek, A., Belani, C., Jankowska, R., Pandya, K., Arnold, S., Brahmer, J., Gitlitz, B., and Govindan, R. (2006) A phase II study of intravenous (iv) Milataxel (M) for the treatment of non-small cell lung cancer (NSCLC) refractory to platinum-based therapy. Journal of Clinical Oncology, 24, s7089.
297. Lockhart, A., Bukowski, R., Rothenberg, M., Wang, K., Cooper, W., Grover, J., Appleman, L., Mayer, R., Shapiro, M., and Zhu, A. (2007) Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors. Cancer Chemotherapy and Pharmacology, 60, 203-209.
298. Kobayashi, J., Ogiwara, A., Hosoyama, H., Shigemori, H., Yoshida, N., Sasaki, T., Li, Y., Iwasaki, S., Naito, M., and Tsuruo, T. (1994) Taxuspines A-C, new taxoids from Japanese yew Taxus cuspidata inhibiting drug transport activity of P-glycoprotein in multidrug-resistant cells. Tetrahedron, 50, 7401-7416.
299. Hosoyama, H., Shigemori, H., Tomida, A., Tsuruo, T., and Kobayashi, J. (1999) Modulation of multidrug resistance in tumor cells by taxinine derivative. Bioorganic & Medicinal Chemistry Letters, 9, 389-394.
300. Ojima, I., Bounaud, P.-Y., Pera, P., and Bernacki, R. (1998) Discovery and development of new taxanes as highly efficient reversal agents for multi-drug resistance in cancer cells. Annals of Oncology, 9, s557.
301. Ojima, I., Bounaud, P.-Y., Takeuchi, C., Pera, P., and Bernacki, R. (1998) New taxanes as highly efficient reversal agents for multi-drug resistance in cancer cells. Bioorganic & Medicinal Chemistry Letters, 8, 189-194.
302. Ojima, I., Borella, C., Wu, X., Bounaud, P.-Y., Fumero, C., Sturm, M., Miller, M., Chakravarty, S., Chen, J., Huang, Q., Pera, P., Brooks, T., Baer, M., and Bernacki, R. (2005) Design, synthesis and SAR of novel taxane-based multi-drug resistance reversal agents. Journal of Medicinal Chemistry, 48, 2218-2228.
303. Brooks, T., Minderman, H., O'Loughlin, K., Ojima, I., Baer, M., and Bernacki, R. (2003) Taxane-based reversal agent modulation of P-glycoprotein-, multidrug resistance protein- and breast cancer resistance protein-mediated drug transport. Molecular Cancer Therapeutics, 2, 1195-1205.
304. Brooks, T., Kennedy, D., Gruol, D., Ojima, I., Baer, M., and Bernacki, R. (2004) Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators. Anticancer Research, 24, 409-415.
305. Benderra, Z., Gaussat, A.-M., Sayada, L., Perrot, J.-Y., Chaoui, D., Marie, J.-P., and Legrand, O. (2004) Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clinical Cancer Research, 10, 7896-7902.
306. Gruol, D., Bernd, J., Phippard, A., Ojima, I., and Bernacki, R. (2001) The use of a novel taxane-based P-glycoprotein inhibitors to identify mutations altering the protein's interaction with paclitaxel. Molecular Pharmacology, 60, 104-113.
307. Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M., Viale, M., Giavazzi, R., and Taraboletti, G. (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clinical Cancer Research, 2, 1843-1849.
308. Taraboletti, G., Micheletti, G., Rieppi, M., Poli, M., Turatto, M., Rossi, C., Borsotti, P., Roccabianca, P., Scanziani, E., Nicoletti, M., Bombardelli, E., Morazzoni, P., Riva, A., and Giavazzi, R. (2002) Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clinical Cancer Research, 8, 1182-1188.
309. Otová, B., Ojima, I., Václaviková, R., Hrdý, J., Ehrlichová, M., Souček, P., Vobořilová, J., Němcová, V., Zanardi, I., Horský, S., Kovář, J., and Gut, I. (2012) Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genes. Investigational New Drugs, 30, 991-1002.
310. Schwartz, E. (2009) Antivascular actions of microtubule-binding drugs. Clinical Cancer Research, 15, 2594-2601.
311. Petrangolini, G., Cassinelli, G., Pratesi, G., Tortoreto, M., Favini, E., Supinio, R., Lanzi, C., Belluco, S., and Zunino, F. (2004) Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in paclitaxel-resistant human ovarian tumour xenograft. British Journal of Cancer, 90, 1464-1468.
312. Frapolli, R., Marangon, E., Zaffaroni, M., Colombo, T., Falcioni, C., Bagnati, R., Simone, M., D'Incalci, M., Manzotti, C., Fontana, G., Morazzoni, P., and Zucchetti, M. (2006) Pharmacokinetics and metabolism in mice of IDN 5390 (13-)N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral C-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. Drug Metabolism and Disposition, 34, 2028-2035.
313. Bloom, B.R. and Murray, C.J. (1992) Tuberculosis: commentary on a reemergent killer. Science, 257, 1055-1064.
314. Kumar, K., Awasthi, D., Berger, W.T., Tonge, P., Slayden, R., and Ojima, I. (2010) Discovery of anti-TB agents that target the cell-division protein FtsZ. Future Medicinal Chemistry, 2, 1305-1323.
315. Romberg, L. and Levin, P.A. (2003) Assembly dynamics of the bacterial cell division protein FtsZ: poised at the edge of stability. Annual Review of Microbiology, 57, 125-154.
316. DeBoer, P.C.R. and Rotherfield, L. (1992) The essential bacterial cell-division protein FtsZ is a GTPase. Nature, 359, 254-256.
317. dePereda, J.M., Leynadier, D., Evangelio, J.A., Chacon, P., and Andreu, J.M. (1996) Tubulin secondary structure analysis, limited proteolysis sites and homology to FtsZ. Biochemistry, 35, 14203-14215.
318. Huang, Q., Kirikae, F., Kirikae, T., Pepe, A., Slayden, R.A., Tonge, P.J., and Ojima, I. (2006) Targeting FtsZ for anti-tuberculosis drug discovery: noncytotoxic taxanes as novel anti-tuberculosis agents. Journal of Medicinal Chemistry, 49, 463-466.